First Look Analysts Research Calls for Tuesday, January 3
This report was sent to Briefing.com subscribers earlier today. Upgrades: > Adaptimmune Therapeutics (ADAP) upgraded to Buy from Neutral at
Read moreThis report was sent to Briefing.com subscribers earlier today. Upgrades: > Adaptimmune Therapeutics (ADAP) upgraded to Buy from Neutral at
Read moreAfter a horrific year, investors soon will be receiving the dreaded fourth-quarter and year-end statements, and they will not be
Read moreUtility stocks are known to be stable investments for plenty of reasons. The demand for utility services remains more or
Read moreKYIV (Reuters) -Numerous blasts were heard in Kyiv and in other places around Ukraine and air raid sirens wailed across
Read moreTo say that 2022 has been a tough year for equities is an understatement, especially given the euphoria of the
Read moreCrypto wallets belonging to Alameda Research were exchanging several crypto tokens for ETH and USDT before swapping them for Bitcoin
Read moreFidelity recently filed for a set of new trademarks in its latest bid to expand into the Metaverse. The applications
Read moreDavid Tepper is a prominent investor and hedge fund manager, who co-founded Appaloosa Management in 1993. Prior to Appaloosa, Tepper
Read moreSHANGHAI (Reuters) -China, grappling with a new wave of COVID-19 infections, took another step towards loosening its pandemic-related restrictions on
Read more